PA
CIM

PharVision Advisers’s Chimera Investment CIM Stock Holding History

PharVision Advisers’s Portfolio CIM Stock Details CIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,332
Closed -$137K – 728
2025
Q3 		$137K Sell
10,332
-11,966
-54% -$167K 0.08% 586
2025
Q2 		$309K Buy
+22,298
New +$285K 0.44% 74
2025
Q1 		– Sell
-12,729
Closed -$178K – 306
2024
Q4 		$178K Buy
+12,729
New +$191K 0.15% 327

Other funds holding CIM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TIM
Thornburg Investment Management Santa Fe, New Mexico $9.63B AUM 35.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.03B AUM 32.21% 1-Year Est. Return
Mirae Asset Global ETFs Holdings
Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $73.7B AUM 53.56% 1-Year Est. Return

PharVision Advisers's CIM Position: Q4 2025 in Review

PharVision Advisers sold out of Chimera Investment (CIM) in Q4 2025, closing a stake of 10,332 shares — an estimated $137K sold.

PharVision Advisers first reported a position in CIM in Q4 2024 and held it in 3 quarters. The position peaked at $309K in Q2 2025. 200 funds tracked by Wall St. Rank hold CIM as of Q4 2025.

  • PharVision Advisers reported no remaining Chimera Investment position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 10,332 Chimera Investment shares in Q4 2025, an estimated $137K.
  • PharVision Advisers first reported a position in Chimera Investment in Q4 2024 and held it in 3 quarters.
  • PharVision Advisers's Chimera Investment position peaked at $309K in Q2 2025.
  • 200 funds tracked by Wall St. Rank held Chimera Investment as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.